Contact: Contact: Philip M. Waldstein, Global Product Manager - Injector Systems 
Telephone: (516)-333-8230, ext. 447
Email: pwaldstein@ezem.com 

E-Z-EM Introduces New CT Injector at RSNA 2001

EMPOWERCT(TM) COMBINES PATENTED EXTRAVASATION DETECTION TECHNOLOGY 
WITH A MODULAR INJECTOR SYSTEM DESIGN

Westbury, New York; November 26, 2001 E-Z-EM, Inc., (AMEX: EZM.A and EZM.B) introduced its 
latest CT injector system, EmpowerCT(TM), at the Radiological Society of North America’s 
87th Scientific Assembly and Annual Meeting, being held in Chicago this week. The modular 
configuration of the new system represents a dramatic departure from conventional concepts 
of CT injector design.

According to E-Z-EM Senior Vice President of Sales and Marketing, Joseph J. Palma, "We started 
development of the EmpowerCT(TM) by rethinking the way injectors have been designed in the past.
These typically hardwired systems have been difficult to modify or upgrade, and offered little 
potential for incorporating new technologies as they emerged. EmpowerCT(TM) is entirely modular. 
The injector, its controller, and our Extravasation Detection Accessory(TM) (EDA(TM)) are all 
functionally separate, so new or upgraded modules can be swapped easily. Combined with the 
system's familiar, Windows-based operating software, this modular design can help reduce repair 
time and makes system upgrades easy to perform."

Exclusive Features Contribute to Patient Safety

Extravasation can occur whenever diagnostic or therapeutic agents - such as ionic and non-ionic 
contrast agents, chemotherapeutic agents, or IV fluids - are administered intravenously. While 
articles have shown that from 0.04% to 1.3% of the 10 million CT contrast procedures performed 
annually in the United States result in an extravasation, the absolute number is substantial 
because the base number of procedures is so large. EDA(TM) technology assists in detecting 
extravasations before they become clinically significant, which minimizes the risk of severe 
skin and subcutaneous tissue damage and the potential need for skin grafts or plastic surgery.

The importance of extravasation detection rises as injector flow rates increase to meet the 
capabilities of modern high-speed CT scanners. This is because with faster injections it takes 
less time for a clinically significant volume of contrast media to be extravasated. As Palma 
points out, "At a flow rate of just 4.5 ml per second it requires only eight seconds to inject 
a bolus the size of a golf ball. Even with the best manual monitoring technique, that does not 
leave very much time to detect the condition and abort the procedure. This is why E-Z-EM 
believes so strongly in the value of assisted extravasation detection with our EDA technology."
E-Z-EM includes this patented, proprietary system as an optional module for the EmpowerCT(TM).

EDA(TM) is only one of several exclusive features of the EmpowerCT(TM) that help enhance patient 
safety. Should a potentially hazardous condition exist, the procedure may be paused immediately 
at the injector head with a handy pendant switch, or by touching any area on the remote control 
touch screen. Response time is further enhanced by voice prompts that immediately alert the 
operator to system status or problems. There is no need to consult text messages on the control 
screen. EmpowerCT(TM) is also provided with a tilt sensor that prevents operation if the 
injector head is not properly positioned to avoid possible air embolism, and a pressure 
limiting system to slow or stop injection should an overpressure condition occur.

Greater Convenience

A variety of features contribute to making EmpowerCT(TM) extremely flexible and easy to use. 
The injector head is free to rotate in either direction to aid in positioning. Graphic displays 
facilitate syringe monitoring, and a unique anatomical interface simplifies protocol selection. 
Automated and manual syringe filling, "on-the-fly" flow rate manipulation, and system arming 
can all be controlled at the injector head. The software even offers an on-line "help" button 
to answer operational questions and aid in system troubleshooting.

"This system incorporates an exceptional number of convenience features into a very small 
package," said Palma. "When you consider ease of operation, modular design, and patient safety, 
you can understand why we believe that EmpowerCT(TM) sets a new standard for CT injector systems." 

About E-Z-EM, Inc. 

E-Z-EM is the world’s largest manufacturer of contrast agents for gastrointestinal radiology. 
The Company’s wholly owned subsidiary, AngioDynamics, manufactures a wide range of products, 
including angiographic, vascular access, thrombolytic, angioplasty, stents, as well as abdominal
infection drainage products. AngioDynamics’ focus is on diagnostic and therapeutic products for 
interventional radiology and other areas of minimally invasive surgery. Enteric Products, Inc., 
another subsidiary, develops, manufactures and markets tests for detection of the ulcer- and 
cancer-causing bacterium Helicobacter pylori. For additional information, please contact Frank 
Kerrigon at 1-800-544-4624, ext. 325, (Email: fkerrigon@ezem.com) or visit our corporate web 
site at www.ezem.com. 

The statements made in this document contain certain forward-looking statements that involve a 
number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans",
"believes", "seeks", "estimates", or variations of such words and similar expressions, are 
intended to identify such forward-looking statements. Investors are cautioned that actual 
events or results may differ from the Company’s expectations. In addition to the matters 
described above, the ability of the Company to develop its products, future actions by the 
FDA or other regulatory agencies, results of pending or future clinical trials, overall 
economic conditions, general market conditions, foreign currency exchange rate fluctuations, 
the effects on pricing from Group Purchasing Organizations, competition, including alternative 
procedures which continue to replace traditional fluoroscopic procedures, as well as the risk 
factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited 
to its Form 10-Q for the quarter ended September 1, 2001, as well as its Annual Report on 
Form 10-K for the year ended June 2, 2001, may affect the actual results achieved by the 
Company.

End